Receptor News and Research

RSS

Discovery of major new treatment target in diseased arteries

Removing a single protein prevents early damage in blood vessels from triggering a later-stage, frequently lethal complication of atherosclerosis, according to research published online today in the journal Nature Medicine. By eliminating the gene for a signaling protein called cyclophilin A (CypA) from a strain of mice, researchers were able to provide complete protection against abdominal aortic aneurysm (AAA).

11 May 2009

New tag could enable more detailed structural studies of mammalian proteins

To say our genes are resourceful is a gross understatement. Through ingenious combinations of a paltry 20 amino acids, the basic building blocks of life, genes engineer all of the tissues and organs that are the marvel of our working bodies.

6 May 2009

New light shed on salt-sensitive hypertension

A high salt intake has been implicated in cardiovascular disease risk for 5000 years. But salt-sensitive hypertension still remains an enigma.

4 May 2009

Discovery of gene associated with narcolepsy

Scientists funded by the National Institutes of Health have identified a gene associated with narcolepsy, a disorder that causes disabling daytime sleepiness, sleep attacks, irresistible bouts of sleep that can strike at any time, and disturbed sleep at night. The gene has a known role in the immune system, which strongly suggests that autoimmunity, in which the immune system turns against the body's own tissues, plays an important role in the disorder.

3 May 2009

Researchers identify a molecular target for quinoline compounds

The full details about the molecules and mechanisms that underlie the development of autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, remain to be discovered.

30 Apr 2009

A negative mGluR5 allosteric modulator shows efficacy in treating acute migraine attacks

When migraine strikes, because of severe pain, often accompanied by nausea and sensitivity to light and sound, sufferers are effectively disabled for up to 72 hours.

30 Apr 2009

Dietary acrylamide not linked to increased lung cancer risk in men

Dietary acrylamide was not associated with an increased risk of lung cancer, according to data from a large prospective case-cohort study in the April 28 online issue of the Journal of the National Cancer Institute.

30 Apr 2009

Wyeth's Conbriza (bazedoxifene) approved in Europe for postmenopausal osteoporosis

Wyeth Pharmaceuticals has announced that the European Commission has granted marketing authorization for Conbriza (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.

27 Apr 2009

Discovery of novel protein which, when over-expressed, leads to a dramatic increase in the generation of A-beta

A defining hallmark of Alzheimer's disease is the accumulation of the amyloid beta protein (A-beta), otherwise known as "senile plaques," in the brain's cortex and hippocampus, where memory consolidation occurs.

27 Apr 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

New scan may lead to better treatment for epilepsy

Australian scientists have found that new technology may help in the treatment of epilepsy.

27 Apr 2009

Research brings new hope, old problems with Alzheimer's disease biomarkers

Brain imaging and cognitive tests may be the gold standards for tracking Alzheimer disease progression, but clinical trials using these procedures are expensive, risky, and time-consuming, making the development of reliable go-betweens a pressing goal for AD researchers.

26 Apr 2009

MicroRNA may link smoking risk gene to neurobiology of addiction

During the past several years, significant progress has been made in identifying susceptibility genes for nicotine dependence through genetic linkage and association analyses.

23 Apr 2009

Lilly granted preliminary injunction to prevent launch of generic Raloxifene

Eli Lilly and Company has announced that the U.S. District Court for the Southern District of Indiana today issued a preliminary injunction to prevent the launch of a generic version of Lilly's medicine Evista (raloxifene HCl tablets) by Teva Pharmaceuticals until the Court renders its final ruling.

22 Apr 2009

Lymphocytes promote cancer spread

Researchers at the UC San Diego School of Medicine and the Moores UCSD Cancer Center have new evidence that a type of immune system cell thought to be part of the first line of defense against breast cancer may also help promote its spread.

22 Apr 2009

Mitochondrial peptide Humanin linked to neuronal cell survival and regulation of glucose metabolism

Recent studies have shown that the mitochondrial peptide Humanin (HN) protects against neuronal cell death such as happens in Alzheimer's disease.

22 Apr 2009

Engineered antibody gives cancer the recognition it deserves

In concept, the human immune system has the power to destroy cancer cells with great specificity.

22 Apr 2009

Mouse model provides a new tool for investigating Wolf-Hirschhorn syndrome

Wolf-Hirschhorn Syndrome (WHS) is a human disease caused by spontaneous genetic deletions.

22 Apr 2009

Novel microparticle-based immune response modifier shows broad effects against recurrent or metastatic cancer

MIS416, a novel microparticle-based immune response modifier, demonstrated the ability to significantly reduce the number and size of metastatic tumors in preclinical mouse models of lung and breast cancers, Innate Therapeutics (formerly Virionyx Corporation) announced.

22 Apr 2009

Study findings have implications for development of pain-relieving drugs

Morphine and other opioids are widely used to treat both acute and chronic pain – yet their benefits are often limited because some people experience side effects or do not respond to them efficiently.

21 Apr 2009